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Abstract 
Gastrointestinal endogenous proteins (GEP) were investigated as a source of 
bioactive peptides. In silico and in vitro methods were used singly or in combination 
to study GEP-derived peptides after simulated digestion. The presence of bioactive 
peptides after in vivo digestion was determined using a porcine model. Bioactivity of 
the peptides was assessed using selected in vitro bioactivity assays, and peptides 
were characterised using sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and mass spectrometry. 
In the in silico study, twenty six different GEP and seven dietary proteins were 
subjected to simulated in silico gastrointestinal (SIGIT) digestion. The predicted 
resultant peptides possessing amino acid sequences identical to those of known 
bioactive peptides were identified by screening them against an online database of 
bioactive peptides (BIOPEP). The predicted number of bioactive peptides released 
after the SIGIT digestion of GEP ranged from 1 (secretin) to 39 (mucin-5AC), while 
those for dietary proteins ranged from 1 (gliadin) to 55 (myosin). Angiotensin-I-
converting enzyme (ACE-I) inhibitory peptide sequences were found in abundance 
in both GEP and dietary proteins. The GEP mucin-5AC and the dietary protein 
myosin were predicted to release the highest number of ACE-I inhibitory peptides 
(38 and 49 peptides respectively), and were found to be comparable in their potential 
to release ACE-I inhibitory peptides. 
Following SIGIT digestion of eleven representative GEP, nineteen novel GEP-
derived peptide sequences were selected by applying quantitative structure-activity 
relationship rules, and were chemically synthesised. Two novel peptides with the 
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amino acid sequences RPCF and MIM, showing dipeptidyl peptidase IV (DPP-IV) 
inhibitory activity and five novel antioxidant (2,2-diphenyl-1-picrylhydrazyl 
(DPPH)- inhibitory and, or ferric reducing antioxidant power (FRAP) activity) 
peptides with amino acid sequences CCK, RPCF, CRPK, QQCP and DCR were 
identified. These results indicate that GEP may contain novel bioactive peptide 
sequences. 
The potential release of bioactive peptides, from four GEP (trypsin, lysozyme, 
mucin, and serum albumin) and a dietary protein (chicken albumin), in the 
gastrointestinal tract (GIT) was investigated using an in vitro digestion model. The 
in vitro digests were screened for ACE-I-, renin-, platelet-activating factor 
acetylhydrolase (PAF-AH)-, and DPP-IV-inhibition, and antioxidant activity. All 
four in vitro GEP digests showed ACE-I inhibition comparable to that of the 
positive control captopril. In comparison to the unfractionated digests, the enriched 
fractions (<3 and <10 kDa) of lysozyme and serum albumin showed greater renin-, 
PAF-AH-, and DPP-IV-inhibition, and antioxidant potential. Over 190 peptide 
sequences were identified from these fractions using mass spectrometry. 
Stomach chyme (SC) and jejunal digesta (JD) were collected from growing pigs that 
were fed a protein-free diet for a period of 3 days. The peptides extracted from SC 
and JD samples were characterized by SDS-PAGE, and their ACE-I-, DPPH-, and 
microsomal lipid peroxidation (MLP)- inhibition, FRAP activity determined. 
Potential bioactive peptides responsible for bioactivity were identified using mass 
spectrometry. SDS-PAGE analysis showed that all of the samples contained a 
heterogeneous mixture of peptides. Porcine JD samples inhibited ACE-I and DPPH, 
while SC samples inhibited MLP. Characterization studies identified over 180 
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peptide sequences from the enriched fractions of SC and JD samples that showed the 
highest activity. Further, a porcine serum albumin peptide sequence 
(FAKTCVADESAENCDKS) was found to be a sub-sequence of a larger sequence 
identified in the in vitro digest of human serum albumin. There was considerable 
inter-animal variation for the bioactivities. This may be attributed to sampling 
effects and, or natural variations in the gut contents, thus underlining the complexity 
involved in in vivo release of bioactive peptides.  
Together, the results indicate: 1) GEP contain abundant encrypted bioactive peptide 
sequences; 2) GEP-derived bioactive peptides display a range of bioactivities; 3) 
GEP-derived bioactive peptides are released during gastrointestinal digestion in 
pigs; 4) GEP may contain numerous novel bioactive peptide sequences encoded 
within their primary sequence. 
In conclusion, the evidence reported here suggests that, like the dietary proteins, 
GEP are also a potentially rich source of exogenously-derived bioactive peptides in 
the gastrointestinal tract. Beyond their primary functions, GEP may act as an 
important cryptomic source of bioactive peptides, given that the amount of GEP 
secreted into the gut is equal to or greater than the dietary protein ingested per day, 
and that up to 80% of GEP are known to be digested. 
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